Journals / Turkish Thoracic Journal / 2021 / Cilt: 22 - Sayı: 6

Association Between Cystic Fibrosis Severity Markers and CFTR Genotypes in Turkish Children

Pages
426–431
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: There seems to be a difference between class I/II CFTR mutations and class III-V mutations on the severity of the disease in cystic fibrosis patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To compare class I/II cystic fibrosis transmembrane conductance regulator (CFTR) mutations to class III-V mutations with regards to cystic fibrosis disease severity markers in children.
📊
Key Findings & Data:The study included 38 cystic fibrosis patients aged between 0.6 and 18 years.
💡
Conclusion & Impact:CONCLUSION: There seems to be a difference between class I/II CFTR mutations and class III-V mutations on the severity of the disease in cystic fibrosis patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

OBJECTIVE: To compare class I/II cystic fibrosis transmembrane conductance regulator (CFTR) mutations to class III-V mutations with regards to cystic fibrosis disease severity markers in children. MATERIAL AND METHODS: This study was designed as a cross-sectional study in Antalya province, located on the south coast of Turkey. The study included 38 cystic fibrosis patients aged between 0.6 and 18 years. The CFTR genotype of the patients was categorized into 2 groups based on the presence or absence of class I or class II mutations in any of the alleles. Group I comprised 8 homozygous, 8 with unknown alleles, and 8 compound heterozygous patients, and group II comprised 11 homozygous and 3 compound heterozygous patients. The groups were analyzed in respect of cystic fibrosis disease severity markers, such as spirometry, ShwachmanKulczycki score, body mass index (BMI), sweat chloride concentration, chronic Pseudomonas aeruginosa infection, annual exacerbation frequency, and severe exacerbations requiring hospitalization during the previous year. RESULTS: In the comparison of group I and group II patients, a significant difference was observed in pancreas insufficiency (83.3% vs. 35.7%; P = .005), chronic P. aeruginosa infection (58.3% vs. 7.1%; P = .002), cough severity score (1.7 ± 1.1 vs. 0.9 ± 1.5; P = .029), number of severe exacerbations requiring hospitalization during the previous year (0.9 ± 1 vs. 0.3 ± 0.8; P = .03), and sweat chloride levels (76.7 ± 15.2 vs. 61 ± 22.3; P = .02). All these values were higher in group I patients. The mean BMI values (15.8 ± 2.2 vs. 17.6 ± 2.8; P = .03) were lower in group I patients. CONCLUSION: There seems to be a difference between class I/II CFTR mutations and class III-V mutations on the severity of the disease in cystic fibrosis patients.

🔖

Cite This Article

BAŞARAN, A., BAŞARAN, A., UYGUN, D. F. K., YILMAZ, E., MOBALLEGH, A., ÖZ, L., ALPER, Ö. M., BİNGÖL, A. (2021). Association Between Cystic Fibrosis Severity Markers and CFTR Genotypes in Turkish Children. Turkish Thoracic Journal, Cilt: 22 - Sayı: 6, 426–431. https://ajindex.com/articles/402959

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993
  2. 73(7):1251- 1254. [CrossRef] 2. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr. 1995
  3. 127(5):705-710. [CrossRef] 3. Boyle MP, De Boeck KD. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2013
  4. 1(2):158-163. [CrossRef] 4. Vankeerberghen A, Cuppens H, Cassiman JJ. The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst Fibros. 2002
  5. 1(1):13-29. [CrossRef] 5. Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis Thorax. 2005
  6. 60(7):558-563. [CrossRef] 6. Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol. 1996
  7. 22(6):387-395. [CrossRef] 7. Welsh MJ, Tsui L-C, Boat TF, et al. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease
  8. vol III. New York: McGraw-Hill
  9. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 2000
  10. 67(2):117-133. [CrossRef] 9. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med. 2012
  11. 2(12):a009548. [CrossRef] 10. Castellani C, Cuppens H, Macek Jr M, et al. consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008
  12. 7(3):179-196. [CrossRef] 11. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003
  13. 361(9370):1671-1676. [CrossRef] 12. ECFS Patient Registry. https://www.ecfs.eu/ecfspr/. Accessed August14, 2019. 13. Emiralioğlu N, Özçelik U, Yalçın E, Doğru D, Kiper N. Diagnosis of cystic fibrosis with chloride meter (Sherwood M926S chloride analyzer®) and sweat test analysis system (CFΔ collection system®) compared to the Gibson Cooke method. Turk J Pediatr. 2016
  14. 58(1):27-33. [CrossRef] 14. Neyzi O, Bundak R, Gökçay G, et al. Reference values for weight, height, head circumference and body mass index in Turkish children. J Clin Res Pediatr Endocrinol. 2015
  15. 7(4):280- 293. [CrossRef] 15. Pressler T, Bohmova C, Conway S, et al. Chronic Pseudomonas aeruginosa infection definition: Eur